European Regulator Deals Blow For Lilly’s Alzheimer’s Drug Kisunla

 
• By Francesca Bruce
  
Lilly will request a CHMP re-examination of its Alzheimer's disease drug Kisunla (Shutterstock)

More from Europe

More from Product Reviews